{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-034321","form_type":"8-K","ticker":"ISPC","cik":"0001558569","company_name":"iSpecimen Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.601820+00:00","generated_at":"2026-06-04T19:27:55.546173+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"iSpecimen FY2023 revenue $9.93M (-4.5% YoY), net loss $11.1M; cash burn improves to $657K in Q4","bullets":["Revenue $9.93M vs $10.40M in 2022; specimen count fell 11% to 24,565 but ASP rose 7% to $404.","Net loss $11.10M ($1.23/sh) vs $10.2M ($1.16/sh); cash ended at $5.01M, down from $15.31M.","Q4 cash burn $657K, down from $4.29M in Q1; quote-to-PO conversion rose 39% vs prior quarters.","Record monthly revenue of ~$1.7M in Dec 2023; over 600 customer orgs and 7,428 registered users.","Entered ATM offering up to $1.5M on March 5, 2024 for additional funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-034321","json":"https://secwatch.observer/filing/0001104659-24-034321.json","markdown":"https://secwatch.observer/filing/0001104659-24-034321.md","text":"https://secwatch.observer/filing/0001104659-24-034321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000110465924034321/0001104659-24-034321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000110465924034321/tm248700d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:27:55.546173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70da52e70302d045114855b6da24bb9f947a5277","claim":"iSpecimen Inc. reported year ended December 31, 2023 results: net income net loss was approximately $11.10 million, EPS (1.23) per share.","evidence_excerpt":"For the year ended December 31, 2023, the net loss was approximately $11.10 million, or (1.23) per share, compared to a net loss of approximately $10.2 million, or $(1.16) per share, for the same period the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000110465924034321/0001104659-24-034321-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Net income","value":"net loss was approximately $11.10 million"},{"label":"EPS","value":"(1.23) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ca8b449f66655275b3d34e82a75f96ad8e125c69","claim":"iSpecimen Inc. reported twelve-month period ended December 31, 2023 results: revenue $9.93 million, net income $11.10 million net loss, EPS (1.23) per share.","evidence_excerpt":"For the year ended December 31, 2023, revenue was approximately $9.93 million, compared to approximately $10.40 million for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000110465924034321/0001104659-24-034321-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"twelve-month period ended December 31, 2023"},{"label":"Revenue","value":"$9.93 million"},{"label":"Net income","value":"$11.10 million net loss"},{"label":"EPS","value":"(1.23) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}